Navigation Links
Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems

RIVER EDGE, N.J., July 6 /PRNewswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today reported that AmeriWater Corporation has adopted the Nephros Dual Stage Ultrafilter (DSU) as a standard component of its MRO portable reverse osmosis water treatment systems for dialysis.

"The Association for the Advancement of Medical Instrumentation (AAMI) Renal Disease and Detoxification Committee has approved the integration of standard RD52 with the new ISO23500 international standards," said Jim Baker, President of AmeriWater.  "When released, the new standard will significantly lower the recommended tolerable endotoxin levels for water used to make dialysate.  It is important that portable water systems can meet these standards on a consistent basis. The Nephros filter provides additional filtration to meet these standards."

"With the new proposed AAMI standards, it became clear that many of the dialysis centers would have to work harder to achieve these new standards, especially the ones that utilize portable RO's because of their sporadic use," said Diane Dolan, CEO, AmeriWater.  "Our decision to add the Nephros filter as a standard component on our portables will help ensure that the water used for dialysis will be of the highest quality for the patients."

"Nephros applauds the proactive step that AmeriWater has taken to meet the new endotoxin standards and is proud to be working together to provide added safety to dialysis patients," said Paul A. Mieyal, acting CEO of Nephros.

About Dual Stage Ultrafilters

The Nephros DSU is FDA approved for filtration of biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures.  Within the U.S., there are approximately 4,500 clinics providing over 50 million dialysis treatments to 350,000 patients annually. To perform dialysis, ultrapure water is crucial to the production of dialysate. Dialysis clinics have water purification systems; however, microbial contaminants can originate from the water treatment system, the water distribution loop, or the dialysate concentrates. The Nephros DSU filters particles down to the 0.005-micron level and addresses dialysate contamination at crucial points: after the reverse osmosis module and at the dialysis machine entrance from the water distribution loop. The DSU filter can be used as the last step in the water purification process to ensure ultrapure water for dialysis procedures. Regular use of Nephros Dual Stage Ultrafilters offers an affordable safety measure when utilized with modern water treatment systems and optimally designed hemodialysis machines.

About MRO Series Water Treatment Systems

The AmeriWater portable MROS and MRO1 water treatment systems are tap water ready.   The compact cabinet RO includes pretreatment options and microbiological filtration for 1-2 patient use.  This unique design has dual chloramines removal carbon cartridges with a special blended carbon block design that satisfies AAMI and CMS requirements.  Also included inside the cabinet is an optional anti-scalant system that removes hardness minerals eliminating the need for a softener.  Disinfection is quick and easy.  With a simple push of the keypad, the MRO series can be disinfected with PAA in only one hour.  This extremely quiet complete system is FDA 510K / ISO 13485 and Health Canada registered.  The addition of the Nephros filter completes the MRO by blocking microbiological contaminants down to 0.005 microns.

About AmeriWater Corporation

AmeriWater is a premier provider of water treatment solutions for dialysis and health care applications. Established in 1995, AmeriWater is headquartered in Dayton, Ohio with regional distributors across the Western Hemisphere. Company founder Jim Baker is a leading industry authority on water quality with over 35 years experience in the field.  For more information, visit

About Nephros, Inc.

Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification.

The Nephros hemodiafiltration ("HDF") system is designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. Nephros ESRD products are sold and distributed throughout Europe.

The Nephros Dual Stage Ultrafilter (DSU) is the basis for the Nephros line of water filtration products. The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins. Nephros's DSUs are being evaluated at several major U.S. medical centers for infection control. The DSU has also been selected for further development by the U.S. Marine Corps for purification of drinking water by soldiers in the field.

For more information about Nephros, please visit our website at  

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros' control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to obtain additional funding when needed or on favorable terms; (ii) to continue as a going concern; (iii) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (iv) to have its technologies and products accepted in current or future target markets; (v) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clinical trials; or (vi) to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros' filings with the SEC.  Investors and security holders are encouraged to read these documents on the SEC's website at  Nephros does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nephros Reports 2010 First Quarter Financial Results
2. Nephros Signs Development Agreement with STERIS
3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
4. Nephros Reports 2009 Third Quarter Financial Results
5. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
6. Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin®
7. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
8. PolyTouch Medical Ltd. Announces the Appointment of Robert D. Fanelli, MD, FACS, FASGE as Medical Advisor
9. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
10. ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
11. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
Post Your Comments:
(Date:10/13/2015)... China Jo-Jo Drugstores, Inc. (NASDAQ ... a leading China-based retail, wholesale and online distributor of ... and retail pharmacies, announced preliminary half year fiscal 2016 ... through , growing 438% year over year, ... China Jo-Jo,s online sales are principally ...
(Date:10/13/2015)...  XiMo AG ( Lucerne , ... Milpitas, California ) announced today the launch ... importance of metathesis chemistry was highlighted by the Nobel ... application. This industrially-relevant application has been utilized in the ... chemicals, and polymers. Georg Fráter , COO ...
(Date:10/12/2015)... -- Apheresis is an invasive process that ... and other components from whole blood. In this procedure, the ... an apheresis machine or a blood cell separator. The apheresis ... other blood components. A selected part of the blood is ... or the patient. It involves the use of devices and ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... "My friend's son suffers from eczema, and ... cheeks," said an inventor from Platteville, Colo. "I came up with this kit as ... the UNTOUCHABLE to prevent a child from rubbing or scratching his or her face. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... platform, ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a technology ... innovative health programs and interventions via mobile devices that provide a framework for ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG ... Summit, GPUG Summit and NAVUG Summit are independent user conferences designed and led ...
(Date:10/13/2015)... ... 2015 , ... In an age where the cost of energy is rising, ... foot than in 2009. The Williamsport Regional Medical Center (WRMC) campus has grown 50 ... eight percent. , According to Facilities Management Administrative Director Dieter Reichmann, this is ...
(Date:10/13/2015)... ... 2015 , ... e-con Systems Inc., a leading embedded design services company specializing ... first RGB-IR pixel format camera with a USB 3.0 interface and e-CAM40_CUMI4682_MOD, ... UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 - a 4-megapixel image ...
Breaking Medicine News(10 mins):